Literature DB >> 17442410

Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.

R M Kagan1, T-S Lee, L Ross, R M Lloyd, M A Lewinski, S J Potts.   

Abstract

The K70E mutation in HIV-1 reverse transcriptase was observed in 10% of virologic non-responders of the abacavir/lamivudine/tenofovir arm of ESS30009, alone, or in mixtures with K65R by population sequencing. Clonal analysis of six ESS30009 K70E isolates failed to identify double mutants carrying K65R+K70E. Site-directed K70E mutants had a replication capacity of 97+/-29%, but only 2.4+/-0.9% for K65R+K70E and 0.01% for K65R+K70E+M184V mutants. K65R+K70E phenotypic fold changes for abacavir, lamivudine and tenofovir were comparable to reported values for K65R alone. In molecular dynamic simulations, the epsilon-amino group of K65 was positioned 2.7+/-0.1A from the gamma-phosphate of the dTTP ligand and stabilized the triphosphate. In the R65 mutant, this distance increased to 4.2+/-0.4A and the interaction energy with the ligand was less favorable, but the K70 epsilon-amino group was repositioned closer to the gamma-phosphate and had a more favorable interaction energy. In the double mutant, E70 could not stabilize the gamma-phosphate, resulting in a more severe defect. The net effect of the atomic-level changes in the double mutant may be to destabilize the pyrophosphate leaving group of the ligand, more severely affecting the catalytic rate of the polymerization reaction than the R65 single mutation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442410     DOI: 10.1016/j.antiviral.2007.03.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

1.  Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

2.  Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

Authors:  Nicolas A Margot; Audun Johnson; Michael D Miller; Christian Callebaut
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

3.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

4.  Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.

Authors:  Christopher J Hoffmann; Johanna Ledwaba; Jin-Fen Li; Victoria Johnston; Gillian Hunt; Katherine L Fielding; Richard E Chaisson; Gavin J Churchyard; Alison D Grant; Jeffrey A Johnson; Salome Charalambous; Lynn Morris
Journal:  Antivir Ther       Date:  2013-06-10

5.  K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Matthew M Schuckmann; Karen A Kirby; Eleftherios Michailidis; Yasuko Sakagami; Shinichi Oka; Kamalendra Singh; Stefan G Sarafianos
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

6.  A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1.

Authors:  Dimitrios Coutsinos; Cédric F Invernizzi; Daniela Moisi; Maureen Oliveira; Jorge L Martinez-Cajas; Bluma G Brenner; Mark A Wainberg
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

7.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

8.  Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Authors:  L L Ross; E Rouse; P Gerondelis; E DeJesus; C Cohen; J Horton; B Ha; E R Lanier; R Elion
Journal:  J Antimicrob Chemother       Date:  2009-12-15       Impact factor: 5.790

9.  Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.

Authors:  Soo-Yon Rhee; Vici Varghese; Susan P Holmes; Gert U Van Zyl; Kim Steegen; Mark A Boyd; David A Cooper; Sabin Nsanzimana; Shanmugam Saravanan; Charlotte Charpentier; Tulio de Oliveira; Mary-Ann A Etiebet; Federico Garcia; Dominique Goedhals; Perpetua Gomes; Huldrych F Günthard; Raph L Hamers; Christopher J Hoffmann; Gillian Hunt; Awachana Jiamsakul; Pontiano Kaleebu; Phyllis Kanki; Rami Kantor; Bernhard Kerschberger; Vincent C Marconi; Jean D'amour Ndahimana; Nicaise Ndembi; Nicole Ngo-Giang-Huong; Casper Rokx; Maria M Santoro; Jonathan M Schapiro; Daniel Schmidt; Lillian Seu; Kim C E Sigaloff; Sunee Sirivichayakul; Lindiwe Skhosana; Henry Sunpath; Michele Tang; Chunfu Yang; Sergio Carmona; Ravindra K Gupta; Robert W Shafer
Journal:  EBioMedicine       Date:  2017-03-19       Impact factor: 11.205

10.  Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

Authors:  Soo-Yon Rhee; Philip L Tzou; Robert W Shafer
Journal:  Viruses       Date:  2021-05-11       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.